Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia

British Journal of Pharmacology

Volumn 168, Issue 4, 2013, Pages 966-977

  Shortall, S E ^a   Green, A R ^a   Swift, K M ^a   Fone, K C F ^a   King, M V ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Adrenoceptors; 5 HT; cathinone; dopamine; dopamine receptors; MDMA; mephedrone; methcathinone; plasma noradrenaline; thermoregulation

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; 5 HYDROXYINDOLEACETIC ACID; ALPHA 1 ADRENERGIC RECEPTOR; CATHINONE; DOPAMINE 1 RECEPTOR; HOMOVANILLIC ACID; METHCATHINONE; NORADRENALIN; SEROTONIN;

5 HYDROXYINDOLEACETIC ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CORPUS STRIATUM; HYPOTHALAMUS; HYPOTHERMIA; MALE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RAT; RECTUM TEMPERATURE; SEROTONIN BRAIN LEVEL; TAIL; THERMOREGULATION;

ADRENERGIC ANTAGONISTS; ALKALOIDS; ANIMALS; BODY TEMPERATURE; BODY TEMPERATURE REGULATION; BRAIN; CATECHOLAMINES; DOPAMINE ANTAGONISTS; HYPOTHERMIA; MALE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, INBRED STRAINS; REGIONAL BLOOD FLOW;

EID: 84872908982     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02236.x     Document Type: Article

References (63)

1. ACMD (2010). Consideration of the cathinones. Available at: http://www.homeoffice.gov.uk/acmd1/acmd-cathinones-report-2010 (accessed 23/9/2010).
2. Alexander SP, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Baumann MH, Zolkowska D, Kim I, Scheidweiler KB, Rothman RB, Huestis MA, (2009). Effects of dose and route of administration on pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine (MDMA) in the rat. Drug Metab Dispos 37: 2163-2170.
4. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192-1203.
5. Bexis S, Docherty JR, (2006). Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve α-Adrenoceptors. Br J Pharmacol 147: 926-934.
6. Blessing WW, Zilm A, Ootsuka Y, (2006). Clozapine reverses increased brown adipose tissue thermogenesis induced by 3,4-methylenedioxymethamphetamine and by cold exposure in conscious rats. Neuroscience 141: 2067-2073.
7. Brenneisen R, Geisshüsler S, Schorno X, (1986). Metabolism of cathinone to (-)-norephedrine and (-)-norpseudoephedrine. J Pharm Pharmacol 38: 298-300.
8. Broadley KJ, (2010). The vascular effects of trace amines and amphetamines. Pharmacol Ther 125: 363-375.
9. Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, et al. (2012). Toxicity of amphetamines: an update. Arch Toxicol 86: 1167-1231.
10. Colado MI, Murray TK, Green AR, (1993). 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol 108: 583-589.
11. Dargan PI, Sedefov R, Gallegos A, Wood DM, (2011). The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal 3: 454-463.
12. Docherty JR, Green AR, (2010). The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol 160: 1029-1044.
13. EMCDDA (2011). Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances. Available at: http://www.emcdda.europa.eu/html.cfm/index116639EN.html (accessed October 2011).
14. Emerson TS, Cisek JE, (1993). Methcathinone: a Russian designer amphetamine infiltrates the rural midwest. Ann Emerg Med 22: 1897-1903.
15. Feyissa AM, Kelly JP, (2008). A review of the neuropharmacological properties of khat. Prog Neuropsychopharmacol Biol Psychiatry 32: 1147-1166.
16. Forster CD, Macdonald IA, (1999). The assay of the catecholamine content of small volumes of human plasma. Biomed Chromatogr 13: 209-315.
17. Gordon CJ, Watkinson WP, O'Callaghan JP, Miller DB, (1991). Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 38: 339-344.
18. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI, (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55: 463-508.
19. Green AR, O'Shea E, Saadat KS, Elliott JM, Colado MI, (2005). Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures. Br J Pharmacol 146: 306-312.
20. Green AR, King MV, Shortall SE, Fone KC, (2012). Lost in translation: preclinical studies on MDMA provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. Br J Pharmacol 166: 1523-1536.
21. Gustavsson D, Escher C, (2009). Mephedrone-Internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance. Lakartidningen 106: 2769-2771.
22. Gygi MP, Gibb JW, Hanson GR, (1996). Methcathinone: an initial study of its effects on monoaminergic systems. J Pharmacol Exp Ther 276: 1066-1072.
23. Gygi MP, Fleckenstein AE, Gibb JW, Hanson GR, (1997). Role of endogenous dopamine in the neurochemical deficits induced by methcathinone. J Pharmacol Exp Ther 283: 1350-1355.
24. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, et al. (2011). 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530-536.
25. Halpern P, Moskovich J, Avrahami B, Bentur Y, Soffer D, Peleg K, (2011). Morbidity associated with MDMA (ecstasy) abuse: a survey of emergency department admissions. Hum Exp Toxicol 30: 259-266.
26. Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, et al. (2012a). Effects of the α2-Adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther 340: 286-294.
27. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, et al. (2012b). The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ('ecstasy') in humans. Clin Pharmacol Ther 90: 246-255.
28. Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Krähenbühl S, et al. (2012c). Duloxetine inhibits effects of MDMA ('ecstasy') in vitro and in humans in a randomized placebo-controlled laboratory study. Plos ONE 7: e36476.
29. Kalant H, (2001). The pharmacology and toxicology of 'ecstasy' (MDMA) and related drugs. Can Med Assoc J 165: 917-928.
30. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, et al. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164: 1949-1958.
31. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, NC3Rs Reporting Guidelines Working Group (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
32. King MV, Spicer CH, Sleight AJ, Marsden CA, Fone KC, (2009). Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-ht6 receptor antagonist, Ro 04-6790, in the Novel Object Discrimination task. Psychopharmacology 202: 111-123.
33. McElrath K, O'Neill C, (2011). Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. Int J Drug Policy 22: 120-127.
34. Macerola AE, Swaby RTR, Jayson R, Korash C, King MV, Shortall SE, et al. (2011). Cathinone: the behavioural and neurotoxic effects in Lister Hooded rodents. J Psychopharmacol 25: A45.
35. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
36. Maskell PD, De Paoli G, Seneviratne C, Pounder DJ, (2011). Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 35: 188-191.
37. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR, (2002). The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol 135: 170-180.
38. Meng H, Cao J, Kang J, Ying X, Ji J, Reynolds W, et al. (2012). Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat. Toxicol Lett 208: 62-68.
39. Meyer MR, Wilhelm J, Peters FT, Maurer HH, (2010). Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 397: 1225-1233.
40. Miller ML, Creehan KM, Angrish D, Barlow DJ, Houseknecht KL, Dickerson TJ, et al. (2012). Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). Drug Alcohol Depend doi: 10.1016/j.drugalcdep.2012.07.003 Jul 23 [Epub ahead of print].
41. Nash JF Jr, Meltzer HY, Gudelsky GA, (1988). Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 245: 873-879.
42. Osorio-Olivares M, Rezende MC, Sepúlveda-Boza S, Cassels BK, Fierro A, (2004). MAO inhibition by arylisopropylamines: the effect of oxygen substituents at the beta-position. Bioorg Med Chem 12: 4055-4066.
43. Parrott AC, (2012). MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans. Drug Alcohol Depend 121: 1-9.
44. Pedersen NP, Blessing WW, (2001). Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci 21: 8648-8654.
45. Pehek EA, Schechter MD, Yamamoto BK, (1990). Effects of cathinone and amphetamine on the neurochemistry of dopamine in vivo. Neuropharmacology 29: 1171-1176.
46. Redfern WS, MacLean MR, Clague RU, McGrath JC, (1995). The role of alpha 2-Adrenoceptors in the vasculature of the rat tail. Br J Pharmacol 114: 1724-1730.
47. Rockhold RW, Carlton FB Jr, Corkern R, Derouen L, Bennett JG, Hume AS, (1997). Methcathinone intoxication in the rat: abrogation by dextrorphan. Ann Emerg Med 29: 383-391.
48. Rodsiri R, Spicer C, Green AR, Marsden CA, Fone KC, (2011). Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats. Psychopharmacology 213: 365-376.
49. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, et al. (2011). Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology 214: 593-602.
50. Shioda K, Nisijima K, Yoshino T, Kuboshima K, Iwamura T, Yui K, et al. (2008). Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicology 29: 1030-1036.
51. Shortall SE, Pillidge KE, King MV, Green AR, Fone KCF, (2011). Behavioural and neurochemical responses to chronic intermittent mephedrone administration in the rat. J Psychopharmacol 25: A38.
52. Shortall SE, Macerola AE, Swaby RT, Jayson R, Korsah C, Pillidge KE, et al. (2012). Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur Neuropsychopharmacol doi: 10.1016/j.euroneuro.2012.09.005 [Epub ahead of print].
53. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. (2012). Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168: 458-470.
54. Sprague JE, Banks ML, Cook VJ, Mills EM, (2003). Hypothalamic-pituitary- thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy). J Pharmacol Exp Ther 305: 159-166.
55. Tariq M, Islam MW, al-Meshal IA, el-Feraly FS, Ageel AM, (1989). Comparative study of cathinone and amphetamine on brown adipose thermogenesis. Life Sci 44: 951-955.
56. Vanattou-Saïfoudine N, McNamara R, Harkin A, (2010). Mechanisms mediating the ability of caffeine to influence MDMA ('Ecstasy')-induced hyperthermia in rats. Br J Pharmacol 160: 860-877.
57. Vardakou I, Pistos C, Spiliopoulou CH, (2011). Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 201: 191-195.
58. Watson DJ, Marsden CA, Millan MJ, Fone KC, (2012). Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int J Neuropsychopharmacol 15: 471-484.
59. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J, (2011a). Mephedrone: use, subjective effects and health risks. Addiction 106: 1991-1996.
60. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F, (2011b). Mephedrone, new kid for the chop? Addiction 106: 154-161.
61. Wood DM, Davies S, Greene SL, Button J, Holt DW, Ramsey J, et al. (2010). Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila) 48: 924-927.
62. Wood DM, Greene SL, Dargan PI, (2011). Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 28: 280-282.
63. Wood DM, Hunter L, Measham F, Dargan PI, (2012). Limited use of novel psychoactive substances in South London nightclubs. QJM 105: 959-964.